The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Gemsar     4-amino-1-[(2R,4R,5R)-3,3- difluoro-4...

Synonyms: Gemzar, DDFC, dFdC, gemcitabinehcl, CHEMBL1637, ...
This record was replaced with 60750.
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

 

High impact information on Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

 

Chemical compound and disease context of Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

 

Biological context of Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

  • Using a day 1 and 8, every-3-week schedule, our purpose was to determine the maximum tolerated dose of irinotecan (CPT-11, Camptosar) that can be administered immediately after gemcitabine (Gemzar) at a dose of 1,000 mg/m2 IV [11].
 

Anatomical context of Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

  • Preliminary evaluation of influence of gemcitabine (Gemzar) on proliferation and neuroendocrine activity of human TT cell line: immunocytochemical investigations [12].
 

Associations of Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine with other chemical compounds

 

Gene context of Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

  • A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing metastatic breast cancer [14].
 

Analytical, diagnostic and therapeutic context of Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

References

  1. Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. Steward, W.P. Br. J. Cancer (1998) [Pubmed]
  2. Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study. Frasci, G., D'Aiuto, G., Comella, P., Thomas, R., Capasso, I., Botti, G., Cortino, G.R., De Rosa, V., Comella, G. Semin. Oncol. (2001) [Pubmed]
  3. A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma. Perez-Zincer, F., Olencki, T., Budd, G.T., Peereboom, D., Elson, P., Bukowski, R.M. Investigational new drugs. (2002) [Pubmed]
  4. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team. Von Hoff, D.D. Investigational new drugs. (1996) [Pubmed]
  5. New antimetabolites in cancer chemotherapy and their clinical impact. Kaye, S.B. Br. J. Cancer (1998) [Pubmed]
  6. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Rosell, R., Crino, L., Danenberg, K., Scagliotti, G., Bepler, G., Taron, M., Alberola, V., Provencio, M., Camps, C., De Marinis, F., Sanchez, J.J., Peñas, R. Semin. Oncol. (2003) [Pubmed]
  7. The current role of gemcitabine in ovarian cancer. Ozols, R.F. Semin. Oncol. (2001) [Pubmed]
  8. Gemcitabine in ovarian cancer. Orlando, M., Mandachain, M. Semin. Oncol. (2001) [Pubmed]
  9. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study. Samlowski, W.E., Gundacker, H., Kuebler, J.P., Giguere, J.K., Mills, G.M., Schuller, D.E., Ensley, J.F. Investigational new drugs. (2001) [Pubmed]
  10. A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus a four-week schedule. Parente, B., Barroso, A., Conde, S., Guimarães, T., Seada, J. Semin. Oncol. (2001) [Pubmed]
  11. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Rocha Lima, C.M., Leong, S.S., Sherman, C.A., Perkel, J.A., Putman, T., Safa, A.R., Green, M.R. Oncology (Williston Park, N.Y.) (2002) [Pubmed]
  12. Preliminary evaluation of influence of gemcitabine (Gemzar) on proliferation and neuroendocrine activity of human TT cell line: immunocytochemical investigations. Dadan, J., Wołczyński, S., Sawicki, B., Chyczewski, L., Azzadin, A., Dziecioł, J., Puchalski, Z. Folia Histochem. Cytobiol. (2001) [Pubmed]
  13. The promise of pharmacogenomics: gemcitabine and pemetrexed. Rosell, R., Taron, M., Sanchez, J.M., Moran, T., Reguart, N., Besse, B., Isla, D., Massuti, B., Alberola, V., Sanchez, J.J. Oncology (Williston Park, N.Y.) (2004) [Pubmed]
  14. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Miller, K.D., Sisk, J., Ansari, R., Gize, G., Nattam, S., Pennington, K., Monaco, F., Sledge, G.W. Oncology (Williston Park, N.Y.) (2001) [Pubmed]
  15. Irinotecan in advanced lung cancer: focus on North American trials. Langer, C.J. Oncology (Williston Park, N.Y.) (2004) [Pubmed]
  16. Role of targeted therapy in non-small cell lung cancer: hype or hope? Langer, C.J. Expert review of anticancer therapy. (2003) [Pubmed]
  17. Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer. Crinò, L., Calandri, C., Maestri, A., Marrocolo, F. Oncology (Williston Park, N.Y.) (2001) [Pubmed]
 
WikiGenes - Universities